Literature DB >> 8505098

Alterations in prostaglandin production in spontaneously hypertensive rat smooth muscle cells.

N Jaiswal1, R K Jaiswal, E A Tallant, D I Diz, C M Ferrario.   

Abstract

We have characterized angiotensin binding sites in cultured smooth muscle cells obtained from the aorta of spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats. In both strains of rats the binding of 125I-angiotensin II (125I-Ang II) in smooth muscle cells was time dependent and reached a maximum at 60 minutes. Scatchard analysis revealed a single binding site in both strains with equilibrium constants (KD) of 5.35 nmol/L in SHR and 3.47 nmol/L in WKY rats. Binding capacities (Bmax) in smooth muscle cells averaged 270 and 150 fmol/mg protein in SHR and WKY rats, respectively. Angiotensin peptides competed for 125I-Ang II binding with an order of potency of Ang II > angiotensin-(1-7) = angiotensin I. In smooth muscle cells of the SHR, basal prostaglandin E2 (PGE2) and prostacyclin (prostaglandin I2 [PGI2]) release were threefold and 15-fold lower than that found in WKY rat smooth muscle cells. Ang II as well as angiotensin-(1-7) stimulated PGE2 and PGI2 release in WKY rat smooth muscle cells. In smooth muscle cells from SHR, Ang II increased the production of both PGE2 and PGI2, whereas angiotensin-(1-7) enhanced only PGE2 but not PGI2 release. There was no significant difference between Ang II-stimulated PGE2 and PGI2 release or angiotensin-(1-7)-stimulated PGE2 production in SHR and WKY rat smooth muscle cells. However, angiotensin-(1-7)-stimulated PGI2 release was significantly lower (p < 0.0005) in SHR compared with WKY smooth muscle cells. Collectively, the data suggest that smooth muscle cells of SHR contain a higher number of angiotensin binding sites.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8505098     DOI: 10.1161/01.hyp.21.6.900

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  The mechanism of acidic pH-induced contraction in aortae from SHR and WKY rats enhanced by increasing blood pressure.

Authors:  K Furukawa; J Komaba; H Sakai; Y Ohizumi
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 2.  Angiotensin peptides and lung cancer.

Authors:  Patricia E Gallagher; Katherine Cook; David Soto-Pantoja; Jyotsana Menon; E Ann Tallant
Journal:  Curr Cancer Drug Targets       Date:  2011-05       Impact factor: 3.428

3.  Vascular smooth-muscle cells contain AT1 angiotensin receptors coupled to phospholipase D activation.

Authors:  E J Freeman; E A Tallant
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

4.  Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control.

Authors:  Alberto Pignone; Angela Del Rosso; K Bridget Brosnihan; Federico Perfetto; Riccardo Livi; Ginevra Fiori; Serena Guiducci; Marina Cinelli; Veronica Rogai; Alessio Tempestini; Francesca Bartoli; Sergio Generini; Carlos M Ferrario; Marco Matucci Cerinic
Journal:  Ann Rheum Dis       Date:  2007-03-14       Impact factor: 19.103

5.  Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and Mice.

Authors:  Yuling Chi; Jean-Francois Jasmin; Yoshinori Seki; Michael P Lisanti; Maureen J Charron; David J Lefer; Victor L Schuster
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

Review 6.  Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy.

Authors:  Christoph Schindler; Peter Bramlage; Wilhelm Kirch; Carlos M Ferrario
Journal:  Vasc Health Risk Manag       Date:  2007

7.  Renal Blood Flow Response to Angiotensin 1-7 versus Hypertonic Sodium Chloride 7.5% Administration after Acute Hemorrhagic Shock in Rats.

Authors:  Maryam Maleki; Mehdi Nematbakhsh
Journal:  Int J Vasc Med       Date:  2016-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.